US Patent

US11413277 — Non-aqueous liquid nimodipine compositions

Method of Use · Assigned to Arbor Pharmaceuticals LLC · Expires 2038-04-16 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects non-aqueous liquid compositions of nimodipine that have improved stability and methods of using them to reduce ischemic deficits in patients with subarachnoid hemorrhage.

USPTO Abstract

Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2804 — Nimotop

Patent Metadata

Patent number
US11413277
Jurisdiction
US
Classification
Method of Use
Expires
2038-04-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Arbor Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.